Atossa Genetics Inc. (NASDAQ:ATOS) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Atossa Genetics Inc. has received a consensus recommendation of "Hold" from five brokerages, with two selling, two buying, and one strongly recommending the stock.
• The average 12-month price target for Atossa Genetics is $6.25, with recent adjustments from analysts leading to varying ratings.
• Atossa Genetics reported a loss of ($0.07) earnings per share in its latest quarter, missing analysts' expectations by one cent.

Shares of Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) have received a consensus recommendation of "Hold" from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.25.

Several research analysts have issued reports on the stock. Zacks Research cut shares of Atossa Genetics from a "hold" rating to a "strong sell" rating in a report on Monday. Ascendiant Capital Markets increased their target price on shares of Atossa Genetics from $7.50 to $7.75 and gave the stock a "buy" rating in a report on Monday, September 22nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Atossa Genetics in a report on Wednesday, October 8th.

Institutional Trading of Atossa Genetics

A number of institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. acquired a new stake in Atossa Genetics in the 2nd quarter worth approximately $2,468,000. Jane Street Group LLC acquired a new stake in Atossa Genetics in the 2nd quarter worth approximately $381,000. Charles Schwab Investment Management Inc. boosted its stake in Atossa Genetics by 40.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company's stock worth $284,000 after purchasing an additional 120,934 shares in the last quarter. Qube Research & Technologies Ltd raised its position in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company's stock worth $346,000 after buying an additional 325,340 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Atossa Genetics during the 2nd quarter worth approximately $321,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Genetics Stock Down 1.9%

Atossa Genetics stock opened at $1.03 on Wednesday. The company has a market cap of $133.05 million, a price-to-earnings ratio of -4.48 and a beta of 1.11. The firm's fifty day moving average is $0.84 and its 200 day moving average is $0.82. Atossa Genetics has a 52-week low of $0.55 and a 52-week high of $1.66.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). On average, equities research analysts anticipate that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.